文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

藏药青鹏软膏治疗急性痛风性关节炎的疗效与安全性:多中心、随机、双盲、安慰剂对照试验方案

Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2022-05-12

本研究为多中心、随机、双盲、安慰剂对照试验方案,拟纳入206例关节疼痛VAS评分≥3分的急性痛风发作成人,按1:1随机分配至青鹏软膏组或安慰剂软膏组,患处局部外用每日两次连续7天,疼痛VAS≥7分时允许使用双氯芬酸钠缓释片作为补救治疗,主要结局为关节疼痛VAS评分和关节肿胀,旨在评估青鹏软膏治疗急性痛风性关节炎的疗效与安全性。

要点

  • 拟纳入206例急性痛风发作且关节疼痛VAS评分≥3分的成人,按1:1随机分组。
  • 青鹏软膏或等量安慰剂软膏患处局部外用,每日两次,连续7天。
  • 治疗期间关节疼痛VAS评分≥7分时,两组均允许使用双氯芬酸钠缓释片作为补救治疗。

核心结论

  • 据作者所知,本研究是首个评估藏药青鹏软膏治疗急性痛风性关节炎疗效的多中心、随机、双盲、安慰剂对照临床试验。
  • 研究结果将为其用于缓解急性痛风性关节炎症状提供证据。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验方案。
  • 拟招募206例急性痛风发作且关节疼痛VAS评分≥3分的成人。
  • 参与者按1:1随机分配至青鹏软膏组或安慰剂组。
  • 青鹏软膏或等量安慰剂软膏患处局部外用,每日两次,连续7天。
  • 治疗期间关节疼痛VAS评分≥7分时,两组均允许使用双氯芬酸钠缓释片作为补救治疗。

主要发现

  • 主要结局为关节疼痛VAS评分,以及采用受累关节宽度和厚度及VAS评分测量的关节肿胀。
  • 其他结局指标包括关节活动度、关节发红、C反应蛋白、血清尿酸、补救药物使用及不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute gouty arthritis (AGA) is an inflammatory arthritis clinically characterized by severe pain, swelling, and restricted movement of joints, which may cause physical disability and decrease quality of life. The use of recommended first-line treatment agents for AGA may be limited by adverse events. There has been a traditional use of alternative therapies for AGA. Tibetan medicine Qingpeng ointment is one of the on-market herbal products used for symptom relief of AGA. Previous clinical studies indicated that Qingpeng ointment can relieve pain, swelling, redness, and dysfunction of joints in patients with AGA. However, there is no rigorous randomized trial to demonstrate its benefit for AGA. In order to evaluate the efficacy and safety of Qingpeng ointment for AGA, we designed a randomized controlled trial. METHODS: This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Two hundred and six adults with acute flare of gout, and visual analogue scale (VAS) score of joint pain ≥ 3 points will be recruited. Participants will be randomly assigned to herbal treatment or placebo group at a ratio of 1:1. Qingpeng ointment, or equal placebo ointment, will be applied topically at involved joints twice a day for consecutive 7 days. Patients in both groups would be allowed giving diclofenac sodium sustained-release tablets as rescue therapy when VAS score of joint pain ≥ 7 points during the treatment. The primary outcomes will be joint pain measured by VAS score, and joint swelling measured using width and thickness of affected joints and VAS score. Other outcome measures will be joint mobility, joint redness, C-reactive protein, serum uric acid, and the use of rescue medicine as well as adverse effect. DISCUSSION: To the best of our knowledge, this study is the first multi-center, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy of Tibetan medicine Qingpeng ointment for AGA. The findings of this study would provide evidence for its use to relieve symptoms of AGA. TRIAL REGISTRATION: ISRCTN ISRCTN34355813 . Registered on 25 January 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shang YX, Dong X, Xie ZM, et al. Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial. Trials. 2022. PMID: 35549757. doi:10.1186/s13063-022-06338-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。